-
公开(公告)号：US20240352538A1
公开(公告)日：2024-10-24
申请号：US18764250
申请日：2024-07-04
发明人： Efrat SHEMA-YAACOBY , Erez NIR , Vadim FEDYUK , Ekaterina ANDREISHCHEVA , Daniel JONES , Abhijeet SHINDE
IPC分类号： C12Q1/6886 , C12Q1/6804
CPC分类号： C12Q1/6886 , C12Q1/6804 , C12Q2600/156
摘要： A method of analyzing nucleosomes is provided. The method comprising: (a) isolating a plurality of nucleosome molecules from a biological sample; (b) enzymatically linking adenine nucleotides to free DNA ends of the plurality of nucleosome molecules, wherein at least a portion of the adenine nucleotides comprises a label, such that the plurality of nucleosome molecules become attached to a labeled poly(A) tail; (c) hybridizing the plurality of nucleosome molecules attached to the labeled poly(A) tail to a solid support coated with poly(T); and (d) imaging the solid support, whereby the plurality of nucleosome molecules are visualized.
-
公开(公告)号：US20240301368A1
公开(公告)日：2024-09-12
申请号：US18672113
申请日：2024-05-23
CPC分类号： C12N9/0065 , C12N15/81 , C12P7/10 , C12Y111/01007
摘要： Recombinant peroxidase enzymes are disclosed having mutations that increase yield when expressed in yeast cells as compared to their corresponding wild-type peroxidase enzyme. Methods of generating are also disclosed as well as uses thereof.
-
公开(公告)号：US20240263202A1
公开(公告)日：2024-08-08
申请号：US18436233
申请日：2024-02-08
发明人： Asaph AHARONI , Guy POLTURAK
IPC分类号： C12P13/22 , A23L3/3463 , A23L3/3526 , A23L3/3544 , A23L5/46 , C07K14/415 , C12N9/02 , C12N9/12 , C12P13/04 , C12P17/12 , C12P19/02
CPC分类号： C12P13/225 , A23L3/3463 , A23L3/3526 , A23L3/3544 , A23L5/46 , C07K14/415 , C12N9/0083 , C12N9/1205 , C12P13/04 , C12P17/12 , C12P19/02 , C12Y207/01095 , A23V2002/00
摘要： The invention provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD6 or related gene and their use for producing L-DOPA from tyrosine and treating dopamine-responsive disorders, such as Parkinson's Disease. The invention also provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD1 and/or CYP76AD6, a nucleic acid encoding a DOPA 4,5-dioxygenase (DOD) enzyme, such as Beta vulgaris DODA1, and, in some cases, a nucleic acid encoding betalain related glucosyltransferase, such as M. jalapa gene cyclo-DOPA 5-O-glucosyltransferase (cDOPA5GT), and their use for producing betalains. Finally, the invention provides chimeric polypeptides, expression vectors, cells, compositions, and organisms, including plants, and their uses in various methods of the invention.
-
公开(公告)号：US20240239886A1
公开(公告)日：2024-07-18
申请号：US18432214
申请日：2024-02-05
发明人： Ido AMIT , Chamutal BORNSTEIN-OVITS , Adam YALIN , Adi MOSHE , Oren BARBOY , Assaf WEINER , Yonatan KATZENELENBOGEN , Diego JAITIN , Fadi SHEBAN
CPC分类号： C07K16/2803 , A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/464411 , A61K45/06 , A61K47/642 , A61P35/00 , A61P37/04 , A61K2039/505 , C07K2317/565 , C07K2317/71
摘要： Provided are antibodies to TREM2 and Gpnmb. Also provided are compositions comprising the antibodies and methods of using same.
-
公开(公告)号：US20240228521A1
公开(公告)日：2024-07-11
申请号：US18554795
申请日：2022-04-14
IPC分类号： C07F9/6561 , A61K31/675
CPC分类号： C07F9/6561 , A61K31/675
摘要： Disclosed herein are 3, 4-didehydro- and 3′-deoxy-3, 4-didehydro-compounds, and pharmaceutical compositions thereof. The 3, 4-didehydro- and 3′-deoxy-3, 4-didehydro-compounds, and pharmaceutical compositions thereof may be used in methods of treating diseases including virus-induced diseases, cancer, autoimmune diseases, immune disorders, and bacterial-associated diseases or infections, or combinations thereof. Examples of viral-induced diseases include viral infections by RNA or DNA viruses, for example SARS-CoV-2, EBV, and BKV.
-
6.发明公开公开(公告)号：US20240165027A1
公开(公告)日：2024-05-23
申请号：US18424973
申请日：2024-01-29
发明人： Jacob KLEIN , Ronit GOLDBERG , Jasmine SEROR
IPC分类号： A61K9/127 , A61K9/00 , A61K9/08 , A61K31/728 , A61K31/77 , A61K31/79 , A61K47/10 , A61K47/32 , A61K47/36 , B65D35/00 , B65D75/36
CPC分类号： A61K9/127 , A61K9/0048 , A61K9/08 , A61K31/728 , A61K31/77 , A61K31/79 , A61K47/10 , A61K47/32 , A61K47/36 , B65D35/00 , B65D75/36
摘要： Formulations (e.g., solutions) comprising one or more water-soluble polymer(s), liposomes, and an aqueous carrier, are provided. The provided solutions are useful for rinsing, and/or immersing therein, a contact lens and/or in the treatment of ocular discomfort, for example, an ocular discomfort associated with a contact lens. Also provided are kits comprising the solution and a contact lens; articles-of-manufacturing comprising the solution and configured for dispending the solution; and methods utilizing the solution.
-
公开(公告)号：US11983607B2
公开(公告)日：2024-05-14
申请号：US18300629
申请日：2023-04-14
发明人： Gil Semo , Ziv Aqua , Oded Melamed , Dan Charash , Serge Rosenblum , Barak Dayan
摘要： A quantum computing system, method and computer readable storage medium involve tuning a whispering-gallery mode optical resonator to support a resonance frequency associated with a transition frequency of an atom. Operation of a laser is controlled to cause the atom to be trapped adjacent the optical resonator and within the evanescent field portion. Based on an atom presence signal from an optical atom presence detector, an indication is provided that the atom is trapped adjacent the optical resonator. A frequency of a cooling laser is controlled to cool the atom, and the optical resonator is configured to define a closed loop-like mode including an evanescent field portion. The trapping laser is configured to cause the atom to be trapped adjacent the whispering-gallery mode resonator, and the cooling laser is configured to manipulate a state of the atom to thereby cool the atom.
-
8.发明公开公开(公告)号：US20240139247A1
公开(公告)日：2024-05-02
申请号：US18408385
申请日：2024-01-09
申请人： THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER , YEDA RESEARCH AND DEVELOPMENT CO. LTD.
IPC分类号： A61K35/17 , A61K39/00 , A61K39/395 , A61P35/00 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N5/10 , C12N15/63
CPC分类号： A61K35/17 , A61K39/001126 , A61K39/001129 , A61K39/3955 , A61K39/39558 , A61K39/4631 , A61P35/00 , C07K16/28 , C07K16/2896 , C07K16/3061 , C12N5/0636 , C12N5/10 , C12N15/63 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/569 , C07K2317/76 , C07K2319/03
摘要： The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 scFv and the second CAR anti-CD138 scFv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.
-
公开(公告)号：US20240117386A1
公开(公告)日：2024-04-11
申请号：US17768228
申请日：2020-10-22
发明人： Ron MILO , Shmuel GLEIZER , Niv ANTONOVSKY , Elad NOOR , Arren BAR-EVEN , Yehudit ZOHAR , Roee BEN NISSAN , Elad HERZ , Yinon Moise BAR-ON
CPC分类号： C12P1/04 , C07K14/195 , C12N1/20 , C12N9/0008 , C12N9/1205 , C12N9/88 , C12Y102/02001 , C12Y207/01019 , C12Y401/01039 , C12Y402/01001
摘要： A recombinant bacteria which is genetically modified to express formate dehydrogenase (FDH), phosphoribulokinase (prk) and Ribulose-Bisphosphate Carboxylase/oxygenase (RuBisCo) is disclosed. The bacteria may be modified to be autotrophic.
-
公开(公告)号：US20240069042A1
公开(公告)日：2024-02-29
申请号：US18387593
申请日：2023-11-07
发明人： Xin Huang , Yihan Li , James Doecke , Michal Eisenbach-Schwartz , Baijun Gu
CPC分类号： G01N33/6896 , G01N33/582 , G01N2800/2821
摘要： Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD11c, CD59, CD91, and CD163 and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.
-
-
-
-
-
-
-
-
-
搜索结果
1599 条记录 (耗时 0.052 秒)
